← Back to Search

Behavioural Intervention

Bright Light Therapy for Sleep Apnea (BrightDaysII Trial)

N/A
Recruiting
Led By Isabella Soreca, MD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Excessive residual daytime sleepiness (Epworth score > 10)
Documented diagnosis of OSA
Must not have
Primary central sleep apnea, needing O2 therapy via nasal cannula
Decompensated congestive heart failure (CHF)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 4 (end of treatment 1), week 8 (end of wash out), week 12 (end of treatment 2)

Summary

This trial explores if bright light therapy (BLT) can reduce daytime symptoms in people with sleep apnea using CPAP, a device that helps them breathe. BLT is a non-drug treatment for sleep disturbances.

Who is the study for?
This trial is for individuals with obstructive sleep apnea (OSA) who still feel very sleepy during the day despite using CPAP machines regularly. They must have used their CPAP for at least 3 months, not have central sleep apnea or certain other health conditions, and cannot be on medications that affect light sensitivity.
What is being tested?
The study tests Bright Light Therapy (BLT) to see if it helps reduce daytime sleepiness in OSA patients who use CPAP. Participants will try both real BLT and a fake version without knowing which is which, each for four weeks, to compare effects.
What are the potential side effects?
Bright Light Therapy may cause eye strain or headaches in some people. Since it's non-pharmacological, there are fewer side effects compared to medication; however, those sensitive to light might experience discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I often feel very sleepy during the day.
Select...
I have been diagnosed with obstructive sleep apnea.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have central sleep apnea and need oxygen therapy through my nose.
Select...
I do not have worsening heart failure that requires hospitalization.
Select...
I am on medication that makes my skin sensitive to certain light.
Select...
I am legally blind.
Select...
I have bipolar disorder and have not received treatment for it.
Select...
I have been diagnosed with narcolepsy.
Select...
My diabetes is not well-controlled (HgA1c over 8%).
Select...
I am currently using bright light therapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 4 (end of treatment 1), week 8 (end of wash out), week 12 (end of treatment 2)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 4 (end of treatment 1), week 8 (end of wash out), week 12 (end of treatment 2) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Epworth sleepiness scale
Change in QIDS score

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: BLTExperimental Treatment1 Intervention
Bright light therapy delivered via glasses
Group II: s-BLTPlacebo Group1 Intervention
Sham Bright light therapy

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,664 Previous Clinical Trials
3,765,723 Total Patients Enrolled
Isabella Soreca, MDPrincipal InvestigatorVA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
1 Previous Clinical Trials
14 Total Patients Enrolled

Media Library

Bright Light Therapy (BLT) (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05917119 — N/A
Obstructive Sleep Apnea Research Study Groups: BLT, s-BLT
Obstructive Sleep Apnea Clinical Trial 2023: Bright Light Therapy (BLT) Highlights & Side Effects. Trial Name: NCT05917119 — N/A
Bright Light Therapy (BLT) (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05917119 — N/A
~40 spots leftby May 2027